Research Paper Volume 11, Issue 9 pp 2551—2564

MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway

Figure 8. Effects of miR-124 on reversing resistance of CD133+ HCC cells to platinum-based chemotherapeutic drugs. (A) Carboplatin IC50 to CD133+ and CD133- HepG2 and Huh7 cells (*P<0.05). (B) Oxaliplatin IC50 to CD133+ and CD133- HepG2 and Huh7 cells (*P<0.05). (C) Effects of miR-124 (50 pmol/mL) on decreasing carboplatin IC50 to CD133+ HepG2 and Huh7 cells (*P<0.05). (D) Effects of miR-124 (50 pmol/mL) on decreasing oxaliplatin IC50 to CD133+ HepG2 and Huh7 cells (*P<0.05).